

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

**4,800**

Open access books available

**122,000**

International authors and editors

**135M**

Downloads

Our authors are among the

**154**

Countries delivered to

**TOP 1%**

most cited scientists

**12.2%**

Contributors from top 500 universities



**WEB OF SCIENCE™**

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.

For more information visit [www.intechopen.com](http://www.intechopen.com)



# Obesity Related Lipid Profile and Altered Insulin Incretion in Adolescent with Polycystic Ovary Syndrome

Annamaria Fulghesu and Roberta Magnini

*Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy*

## 1. Introduction

Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder, present in 5 - 7% of women of reproductive age. The diagnosis of PCOS was made according to Rotterdam criteria in presence of at least two of the following: 1) oligomenorrhea and/or anovulation; 2) hyperandrogenism (clinical and/or biochemical); 3) polycystic ovaries with the exclusion of other etiologies (1). The disorder is characterized by irregular menstrual cycle, chronic anovulation and hyperandrogenism. Women with PCOS demonstrate marked clinical heterogeneity: the commonly associated features of hirsutism, acne, polycystic-appearing ovaries, obesity and acanthosis nigricans are neither uniform nor universal (2-3). In time the disorder may lead to onset of hyperinsulinemia, insulin resistance, gestational diabetes, early onset of type 2 diabetes mellitus (DM), dyslipidemia and cardiovascular disease (CVD) (4-5).

PCOS is characterized by a complex physiology implicating an interaction with environmental and genetic factors, resulting in a broad spectrum of reproductive and metabolic disorders. (6-7) Adult females with PCOS may be at increased risk for atherosclerotic cardiovascular disease (CVD) due to increased prevalence of obesity and central adiposity as well as to hypertension, hyperinsulinemia, type 2 DM, and dyslipidemia in these patients (8). The prevalence of obesity and consequently the presence of metabolic abnormalities reported in Italian and American published studies differs considerably, underlining the presence of important ethnic differences. (9, 10, 11, 12).

A percentage ranging from 30-75% of women with PCOS are obese, European women generally weighing less than their American counterparts (20,21). Hyperinsulemia and/or insulin resistance (IR) are frequently manifested in obese, and to a lesser extent (50%) in lean, PCOS patients (3, 13, 14). Hyperandrogenaemia, hyperinsulemia and obesity are considered as risk factors for the development of hypertension and dyslipidemia, diabetes mellitus and coronary disease in PCOS (15-16). The causes of metabolic disorders in PCOS remain to be clarified, but include obesity-related IR, an intrinsic abnormality of postreceptor insulin signaling (e.g. excess serine phosphorylation), and abnormal insulin secretion. On the other hand, increased resistance to insulin is a hallmark of the onset of normal pubertal development with natural to pre-pubertal values at the end of puberty in non-obese subjects. Consequently, in early adolescence a physiological resistance to insulin should be taken into account (12).

Dyslipidemia in PCOS is frequently manifested and is characterized by elevated plasma levels of low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL) and triglycerides with concomitantly reduced concentration of high-density lipoproteins (HDL) in obese subjects (17, 18). A decrease in HDL, rise in triglyceride, VLDL, and LDL levels, as well as qualitative disorders of the LDL have all been described in young and adult PCOS (19). Moreover, recent data have shown a higher prevalence of metabolic syndrome in adolescent PCOS compared to controls (20) as well as an early impairment of endothelial structure and function even in non-dyslipidemic subjects with PCOS syndrome (21). Nevertheless, metabolic disorders in PCOS have not been extensively studied in the adolescent population. Several studies have shown how both lean and obese adolescents with PCOS appear to present an increased risk of both metabolic disorders and impaired glucose tolerance and diabetes (22), similar to their adult counterparts. A previous study carried out by our group demonstrated that the Italian young PCOS population is characterized by a high incidence of insulin alterations also in presence of normal weight and normal peripheral insulin resistance (12). Although the prevalence of dyslipidemia differs between PCOS subjects and young healthy girls, it however remains to be clarified whether dissimilarities in dyslipidemia occur in relation only to BMI or also to alterations to the insulin metabolism and/or hyperandrogenemia.

Carmina recently demonstrated that MBS in women with PCOS is less common in Southern Italy compared to rates reported in the USA, the former reaching only 8.2% compared to a prevalence of 43-46% reported by US authors (23). The prevalence of MBS in the adult Italian PCOS population is higher than in control population matched for BMI, suggesting that body weight may be only in part responsible for this metabolic disorder (24).

Although few studies have investigated the latter condition in adolescents, it could prove to be of considerable importance in view of the health implications involved, requiring medical counseling to implement an adequate change in lifestyle. Likewise, obesity rate in adolescent PCOS subjects differs between Europe and the USA. In Sardinia, the incidence of obesity is lower than throughout the rest of Italy, with only 3-4% of high school female population presenting a BMI >25 (25). A combination of genetic factors, different lifestyle and diet are likely involved. In view therefore of the regional peculiarity, the patient population attending our Clinic was deemed to be of interest.

Therefore it is important to understand the relationship between lipid pattern and BMI, hyperinsulinemia and/or insulin resistance and circulating androgens in adolescent PCOS. In a study carried out in July 2005 to the Adolescent Center for gynecological diseases of the Department of Obstetrics and Gynecology, University of Cagliari, San Giovanni di Dio Hospital seventy-one adolescent (age 13-18) subjects affected by PCOS were recruited for this study. On the basis of the various aspects linking PCOS dyslipidemia and CVD risk, the present study was designed to investigate the influence of BMI and insulin metabolism derangement on lipid levels. All subjects were screened for other causes of hyperandrogenism, such as androgen secreting tumors and congenital adrenal hyperplasia (tested by evaluation of 17-dihydroxyprogesterone). All subjects were euthyroid and devoid of hyperprolactinemia, diabetes mellitus and cardiovascular disease. No subjects had taken hormonal contraceptives or other type of medication or been on a diet that may have affected lipid profile, carbohydrate metabolism or insulin levels for at least 3 months preceding the study. No subjects were either smokers or drinkers. No subjects practiced sports on a regular basis (3 or more 20-min sessions of aerobic exercise per week).

These patients were linked with a control group consisting of healthy patients referred to the Adolescent centre for ultrasound screening of ovarian disease.

Control subjects and PCOS were studied 5 to 8 days following menstrual bleeding, which was progestin-induced in amenorrhoeic patients. All patients were studied at least 15 days following Medroxy-Progesterone-Acetate administration (MAP 10 mg for 5 days). At the time of admittance to the study the presence of a dominant follicle, recent ovulation, or luteal phase was excluded by ultrasound examination and serum P evaluation. Height and weight were measured on the morning of testing. Waist and hip circumference were measured as previously referred. Blood pressure was measured in the second position and in the right arm (26) after 15 minutes resting. The hormonal study (after 12 hours overnight) included baseline plasma determination of LH, FSH, Estradiol (E2), Androstenedione (A), Testosterone (T), Dehydroepiandrosteronesulphate (DHEAS), 17hydroxyprogesterone (17-OHP) and Sex-hormone-binding globulin (SHBG). Lipid assay was performed to measure total cholesterol level, high-density lipoprotein cholesterol level (HDL), low-density lipoprotein cholesterol level (LDL) and triglyceride level. Homocysteine levels were also determined.

Adolescents meeting three or more of the following criteria were diagnosed with MBS: waist circumference of at least 90th percentile for age and gender; systolic or diastolic blood pressure at least 90th percentile for age, height and gender; fasting TG at least 110mg/dl (90th percentile for age); fasting HDL not exceeding 40mg/dl (10th percentile for age); and fasting glucose at least 110mg/dl.

Subsequently, patients underwent a 75-g oral glucose tolerance test (OGTT). Insulin, C-peptide, and glucose serum concentrations were analyzed prior to (time 0) and 30, 60, 90, 120 and 180 min after oral glucose load. A normal glycemic response to OGTT was defined according to the criteria of the National Diabetes Data Group (27). Insulin, C-peptide and glucose response to glucose load were expressed as area below the curve (AUC), calculated according to the trapezoidal rule. The homeostatic index of IR (HOMA) was calculated as follows:  $HOMA = [\text{fasting insulin } (\mu\text{U/ml}) \times \text{fasting glucose } (\text{mmol/L} / 22, 5)]$ . (28) The body mass index (BMI) was calculated according to the following formula: body weight in kilograms/ height in m<sup>2</sup>. Normal weight was considered as  $18 \leq \text{BMI} \leq 25$ . The degree of hirsutism was quantified using Ferriman and Gallwey (F-G) score (28).

No differences were observed with regard to the presence of overweight and obese subjects between PCOS and controls (30% vs. 23%); a similar finding was obtained also for waist measurement and WHR, confirming that obesity is not a common finding in young PCOS subjects in the population studied. Moreover, no subjects affected by metabolic Syndrome or diabetes either among PCOS or in the control group were detected. No differences were revealed in lipid levels between PCOS and controls. In addition, no differences were reported for any of the fasting metabolic parameters (i.e. Glucose fasting insulin, HOMA ratio), whilst a higher insulin response under OGTT was obtained for PCOS subjects. On the other hand, statistical correlations clearly demonstrated the influence produced by BMI and waist measurement on HDL, triglyceride and LDL levels. However, dividing the population into tertiles for BMI and waist measurement significant differences were revealed for both HDL and LDL levels in lean overweight and obese subjects and in relation to the presence of visceral fat. The above features have also been reported by several authors carrying out studies on young subjects.

Glueck published a study regarding PCOS and regular cycling adolescents in USA demonstrating a higher prevalence of obesity and dyslipidemia in PCOS.

However, when subjects were matched one-by-one for BMI and age, differences in lipids were no longer significant. In a recent paper on young obese subjects Shroff failed to demonstrate any difference in lipid as well as traditional CV factors in PCOS and control populations, but demonstrated a higher BMI in subjects presenting subclinical coronary atherosclerosis (CAC) (10). In young subjects from southern Italy, Orio demonstrated normal lipid levels in lean PCOS even in the presence of increased dimensions of heart ventricles. The above findings all seem to indicate that rather than being an insulin-correlated factor BMI may well be implicated in lipid alteration. On the other hand, the presence of increased waist measurements in PCOS population suggests that the presence of visceral fat may represent an additional risk factor, independent from BMI in PCOS. The influence of insulin on lipid profile was also determined.

Indeed, to date very few authors have investigated this aspect: Mather found a significant increase in traditional CV risk factors in PCOS women with fasting hyperinsulinemia in respect to their normoinsulinemic counterparts; this difference persisted when BMI was included as covariate. (29) Through reduction of hyperinsulinemia by means of metformin treatment Banazewska obtained a significant increase of HDL and reduction of triglycerides in a group of 43 adult PCOS. Our group recently published a paper on the peculiar insulin derangement observed in a population of normal weight young PCOS demonstrating a low incidence of insulin resistance but high incidence of hyperinsulinemia under OGTT (30). This peculiar metabolic alteration was confirmed in the present sample, thus allowing the separation of hyperinsulinemia from peripheral insulin resistance in data analysis.

Ibanez et al. also demonstrated higher serum insulin levels after OGTT with normal insulin sensitivity in a population of adolescent girls with PCOS. The causes underlying the increased response of  $\beta$ -cells in these subjects are, as yet, unknown. It is not clear whether high levels of insulin necessarily indicate the presence of a disorder although it may be hypothesized that adaptation to the chronic risk of hypoglycemia in hyperinsulinemic subjects could lead to IR after some time. Moreover, our group recently demonstrated that a normal HOMA score is not sufficient to exclude early metabolic abnormalities such as hyperinsulinemia in young lean PCOS subjects. Hyperinsulinemia per se could contribute toward onset of hyperandrogenism independently of peripheral IR. (12)

In this study was found a significant negative correlation between HDL and fasting insulin and HOMA, but this correlation was no longer significant when the influence of BMI was excluded, whereas insulin AUC was not related to any lipid parameters.

Furthermore, although the PCOS sample studied here was divided into tertiles on the basis of both insulin resistance and insulin AUC levels, the data obtained clearly indicate the failure to detect any relationship between insulin levels and lipid profile. Nevertheless, surprisingly a positive correlation was observed between A levels and HDL and a negative correlation between A and triglycerides. Reports present in literature did not afford any explanation for this result. A negative effect of A on HDL levels has previously been reported in males to whom A supplements had been administered (31). Moreover, exogenous T is reported to influence negatively HDL via hepatic lipase (HL) (31) an enzyme that increases the clearance of HDL. Less is known about the regulation of HDL by endogenally-derived androgens. A study performed in women with PCOS was not able to demonstrate any correlation between T and HDL. Considerable controversy exists as to the effect of androgens on lipoprotein lipase (LPL) activity.

In obese women LPL activity correlated positively with plasma free testosterone (32), whereas in women with PCOS a correlation with LPL activity was demonstrated.

Other authors have attributed to coexisting (29) insulin resistance the negative effect of androgen observed on lipid profile. In this case, the low incidence of insulin resistant subjects in a population may explain this unexpected result.

In conclusion, no lipid differences were revealed between our population of adolescent PCOS from southern Italy and controls.

Anthropometric characteristics (BMI, waist measurement and WHR) are the main parameters correlated to lipid derangement, confirming the importance of treating obesity at an early age to prevent onset of complex metabolic syndromes in the future. The latter may be of particular importance in PCOS populations in which insulin alterations (hyperinsulinemia and insulin resistance) are well known peculiarities potentially capable of influencing the long-term evolution of this endocrine disorder towards CVD and diabetes mellitus. A targeted support program should be set up for these young patients aimed at altering life style with the specific aim of reducing BMI and preventing onset of dyslipidemia.

	PCOS (n°71)	CONTROLLI (n°94)	P
Age (years) (M±ES) (range 13-19)	18,61 ± 0,4	18,10 ± 0,38	NS
BMI (kg\m <sup>2</sup> ) (M±ES)	23,97 ± 0,72	22,56 ± 0,50	NS
Overweight (BMI 25 - 29) (%)	10%	11%	
Obesity (BMI > 29) (%)	20%	13%	
Waist (cm) (M±ES)	78,60 ± 1,79	75,56 ± 1,18	NS
WHR (M±ES)	0,77 ± 0	0,77 ± 0	NS
Hirsutism (score F&G) (M±ES)	11,24 ± 0,67	6,7 ± 0,45	0,005°
LH (IU/L)(M±ES)	5,21 ± 0,55	4,19 ± 0,36	NS
FSH (IU/L)(M±ES)	6,42 ± 0,63	5,96 ± 0,19	NS
E <sub>2</sub> (pmol/L)(M±ES)	129,30 ± 20,58	136,81 ± 13,25	NS
A (nmol/L)(M±ES)	0,08 ± 0	0,05 ± 0	0,005°
Tot T(nmol/L)(M±ES)	0,02 ± 0	0,01 ± 0	0,005°
17OHP (ng/mL)(M±ES)	1,49 ± 0,18	1,18 ± 0,07	NS
DHEAS (µmol/L)(M±ES)	2,05 ± 0,12	1,6 ± 0,09	NS
SHBG (nmol/L)(M±ES)	65,83 ± 4,54	71,18 ± 3,35	NS

°P < 0,05

Table 1. Shows the clinical and hormonal characteristics of PCOS population vs. Control group. No significant differences were revealed in age, body weight, waist and WHR between PCOS and control group. Likewise, no differences were observed in the incidence of overweight or obesity in the two groups. As expected, the prevalence of hirsutism and circulating androgen levels were higher amongst PCOS.

	<b>PCOS (n° 71)</b>	<b>CONTROLLI (n°94)</b>	<b>P</b>
<b>Fasting Glucose (mmol/L)(M±ES)</b>	81,13 ± 0,65	88,00 ± 3,27	NS
<b>Fasting Insulin (pmol/L)(M±ES)</b>	119,98 ± 6,14	96,68 ± 4,73	NS
<b>HOMA (M±ES)</b>	61,02 ± 3,09	57,81 ± 2,41	NS
<b>I-AUC 180 min (UI/ml)(M±ES)</b>	21069 ± 978,39	16578 ± 729,37	0,05°
<b>Cholesterol (mg/dl)(M±ES)</b>	166,48 ± 3,53	169,51 ± 2,62	NS
<b>HDL-Cholesterol (mg/dl)(M±ES)</b>	54,26 ± 1,44	51,25 ± 0,89	NS
<b>LDL-Cholesterol (mg/dl)(M±ES)</b>	96,78 ± 3,08	104,55 ± 2,34	NS
<b>Cholesterol/ HDL (mg/dl)(M±ES)</b>	3,16 ± 0,09	3,37 ± 0,07	NS
<b>Triglycerides (mg/dl)(M±ES)</b>	73,91 ± 3,75	78,35 ± 3,86	NS
<b>Homocysteine (µmol/L) (M±ES)</b>	8,16 ± 0,20	7,68 ± 0,25	NS
<b>PCR (M±ES)</b>	2,04 ± 0,36	0,89 ± 0,11	NS

° P < 0,05

Table 2. Reports the metabolic features of PCOS and control group. Fasting metabolic indexes detected for glucose, insulin and HOMA were similar between the two groups. On the contrary, insulin secretion after glucose load (I-AUC) was significantly higher in PCOS subjects. Total cholesterol, HDL, LDL, triglycerides and homocysteine levels did not differ between PCOS and control groups

	<b>Cholesterol</b>	<b>LDL-Cholesterol</b>	<b>HDL-Cholesterol</b>	<b>Triglycerides</b>
<b>BMI (kg\m<sup>2</sup>)</b>	R = 0,0727	R = 0,2579 <sup>•</sup>	R = - 0,404 <sup>▪</sup>	R = 0,1576
<b>WAIST (cm)</b>	R = 0,0869	R = 0,2960 <sup>•</sup>	R = - 0,5934 <sup>▪</sup>	R = 0,1704
<b>WHR (cm)</b>	R = 0,1645	R = 0,2872 <sup>•</sup>	R = - 0,1853	R = 0,1362
<b>A (nmol/L)</b>	R = 0,0136	R = - 0,0523	R = 0,3705 <sup>▪</sup>	R = -0,2948 <sup>•</sup>
<b>Tot T (nmol/L)</b>	R = - 0,1016	R = - 0,0948	R = 0,0012	R = - 0,0157
<b>FSH (mIU/L)</b>	R = - 0,0134	R = - 0,0143	R = 0,0623	R = - 0,0687
<b>E2(pmol/L)</b>	R = - 0,1011	R = - 0,0895	R = 0,0698	R = - 0,1984
<b>DHEAS (µmol/L)</b>	R = - 0,0498	R = - 0,0022	R = - 0,0447	R = - 0,0441
<b>HOMA</b>	R = 0,0762	R = 0,1770	R = -0,3335	R = - 0,0214
<b>I-AUC 180 min(UI/ml)</b>	R = - 0,0098	R = - 0,0272	R = - 0,0701	R = - 0,0287
<b>SHBG (nmol/L)</b>	R = - 0,0689	R = - 0,1514	R = 0,1102	R = 0,1013
<b>17OHP (nmol/L)</b>	R = 0,0418	R = 0,0582	R = 0,0854	R = - 0,1720
<b>Homocysteine (µmol/L)</b>	R = - 0,0670	R = - 0,0786	R = 0,0463	R = - 0,1108 <sup>▪</sup>
<b>Fasting Glucose</b>	R = 0,0049	R = 0,0260	R = -0,0829	R = 0,0643
<b>Fasting Insulin</b>	R = 0,0586	R = 0,1557	R = -0,3314	R = -0,0174

P < 0,05


P < 0,01

P < 0,001

Table 3. Illustrates linear regression relationship featured between lipid and physical, hormonal and metabolic parameters. Total cholesterol levels were significantly related to WHR but not to other antropometric parameters. On analyzing cholesterol fractions LDL levels were found to correlate positively with BMI, Waist, WHR and HOMA but not with I-AUC. HDL results correlated in a markedly negative manner with the same physical parameters as BMI, WHR and waist circumference. Moreover, HDL was negatively correlated with both fasting insulin and HOMA but not I-AUC. Finally, HDL was positively correlated with circulating A and negatively with circulating T levels.

Triglycerides appeared to correlate positively with BMI, Waist and WHR, and negatively with A levels. Homocysteine levels correlated positively with plasma triglyceride content. In view of the potential capacity of BMI to affect insulin sensitivity, conditional regression analysis was performed on HOMA and lipid assays to exclude any possible influence of BMI: HOMA resulted as being no longer correlated with any lipid parameter. To determine whether lipid alterations were primarily caused by increased BMI, lipid assay was repeated stratifying the population into 3 weight categories: normal weight, overweight and obese, and waist measurements were classified (normal and excessive).




BMI (kg\m<sup>2</sup>)

P < 0,05 LDL BMI < 25 VS BMI 25-29

P < 0,05 LDL BMI < 25 VS BMI > 29

P < 0,05 HDL BMI < 25 VS BMI > 29

## WAIST (cm)




P < 0,05 LDL WAIST < 85 VS LDL WAIST > 85

P < 0,05 HDL WAIST < 85 VS HDL WAIST > 85

Fig. 1. Shows the lipid levels in relation to the BMI and the waist of PCOS group. Normal weight and normal waist subjects featured lower LDL and Higher HDL compared to increased waist overweight or obese counterparts. On the other hand, in order to evaluate the influence of metabolic alteration subjects were also stratified on the basis of both HOMA and Insulin AUC values (fig.2).

HOMA



I-AUC (UI/ml)




Fig. 2. Shows lipid levels in subjects divided into tertiles for both HOMA and Insulin AUC levels. Similar lipid values were demonstrated in all subjects.

	<b>Cholesterol</b>	<b>LDL- Cholesterol</b>	<b>HDL- Cholesterol</b>	<b>Triglycerides</b>
<b>BMI (kg\m<sup>2</sup>)</b>	R = 0,0800	R = - 0,0017	R = - 0,4762▪	R = 0,6962
<b>WAIST (cm)</b>	R = 0,1410	R = 0,0753	R = - 0,4253▪	R = 0,6765
<b>WHR (cm)</b>	R = 0,0326	R = - 0,1535	R = - 0,1878	R = 0,4262
<b>A (nmol/L)</b>	R = - 0,1921	R = - 0,0280	R = - 0,1845	R = 0,0007
<b>Tot T (nmol/L)</b>	R = - 0,3425	R = - 0,4544▪	R = - 0,1377	R = 0,3692
<b>FSH (IU/L)</b>	R = 0,3094	R = 0,3909▪	R = 0,3711▪	R = - 0,1603
<b>E2(pmol/L)</b>	R = 0,0150	R = 0,0124	R = - 0,0264	R = - 0,0876
<b>DHEAS (µmol/L)</b>	R = 0,1230	R = 0,1925	R = - 0,1793	R = 0,2206
<b>SHBG (nmol/L)</b>	R = - 0,2226	R = - 0,2834	R = 0,0655	R = - 0,0942
<b>17OHP (nmol/L)</b>	R = - 0,0925	R = - 0,0586	R = 0,1667	R = - 0,3703▪
<b>HOMA</b>	R = 0,4724	R = 0,5140	R = 0,2293	R = - 0,0123
<b>I-AUC 180 min(UI/ml)</b>	R = - 0,0021	R = 0,0331	R = - 0,3391	R = 0,2882
<b>Homocysteine (µmol/L)</b>	R = 0,2148	R = 0,1214	R = - 0,2604	R = 0,5656▪
<b>Fasting Glucose</b>	R = 0,0440	R = 0,1325	R = - 0,1952	R = - 0,0396
<b>Fasting Insulin</b>	R = 0,1226	R = 0,1315	R = 0,0435	R = 0,0972

P < 0,05

P < 0,01

P < 0,001

Table 4. Linear relationships between lipid assays and physical endocrine and metabolic parameters in CONTROLS.

	Cholesterol	LDL- Cholesterol	HDL- Cholesterol	Triglycerides
<b>BMI (kg\m<sup>2</sup>)</b>	R = 0,1058	R = 0,2252	R = - 0,3930	R = 0,2933
<b>WAIST (cm)</b>	R = 0,1298	R = 0,2624	R = -0,3756	R = 0,2856
<b>WHR (cm)</b>	R = 0,2174	R = 0,3039	R = - 0,1924	R = 0,2063
<b>E2(pmol/L)</b>	R = - 0,0912	R = - 0,0912	R = 0,0541	R = - 0,1495
<b>A (nmol/L)</b>	R = - 0,0401	R = - 0,0953	R = 0,2933	R = -0,2400
<b>Tot T (nmol/L)</b>	R = - 0,1848	R = - 0,2191	R = 0,0181	R = 0,0085
<b>SHBG (nmol/L)</b>	R = - 0,1260	R = -0,1973	R = 0,1038	R = 0,0368
<b>Fasting Glucose</b>	R = 0,0107	R = 0.0800	R = - 0,1425	R = -0,0092
<b>Fasting Insulin</b>	R = 0,0773	R = 0,1239	R = - 0,1960	R = 0,0109
<b>HOMA</b>	R = 0,1349	R = 0,2269	R = - 0,2800	R = 0,0021
<b>I-AUC 180 min(UI/ml)</b>	R = 0,0324	R = 0,0550	R = - 0,0930	R = 0,0123
<b>Homocysteine (µmol/L)</b>	R = 0,0764	R = 0,0209	R = - 0,0656	R = 0,2863

P < 0,05

P < 0,01

P < 0,001

Table 5. Linear relationships between lipid assays and physical endocrine and metabolic parameters in all patients.

## 2. References

- [1] The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Human Reproduction* 19: 41,47
- [2] Hacıhanefioglou B. Polycystic ovary syndrome nomenclature: chaos? *Fertility and Sterility* 2000 73, 1261-1262.2.
- [3] Ancien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez JA, Ancien M, Mauri M, Alfayate R. Insulin, androgens and obesity in women with and without Polycystic ovary syndrome: a heterogeneous group of disorders. *Fertility and Sterility* 1999 72, 32-40


- [4] Franks S. Polycystic ovary syndrome. *The New England Journal of Medicine* 1995 333: 853-861
- [5] Ehrmann DA, Barnes RB, Rosenfield RI, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with Polycystic ovary syndrome. *Diabetes Care* 1999 22: 141-14626.
- [6] Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. *Human. Reproduction. Update* 2005 11, 631-643
- [7] Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D. Polycystic ovary syndrome: the influence of environmental and genetics factors. *Hormones (Athens)* 2006 5, 17-3428.
- [8] Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. *Clinical Endocrinology (Oxf)* 1992 37: 119-125
- [9] Teimuraz Apridonidze, Paulina A. Essah, Maria J. Iuorno and John E. Nestler. Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome. *Journal of Clinical Endocrinology and metabolism* 2005 Apr;90(4):1929-35
- [10] Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. *Journal of Clinical Endocrinology and metabolism* 2007 Dec;92(12):4609-14
- [11] Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, Lombardi G, and Lobo RA. Evidence of altered adipocyte function in polycystic ovary syndrome. *European Journal of Endocrinology* 2005 Mar;152(3):389-94
- [12] Fulghesu AM, Angioni S, Portoghese E. Milano F, Batetta B, Paoletti AM, Melis GB. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. *Fertility and Sterility*. 2006 Aug;86(2):398-404
- [13] Chang RJ, Nakamura RM, Judd HL, & Kaplan SA. Insulin resistance in nonobese patients with Polycystic ovarian disease. *Journal of Clinical Endocrinology and Metabolism* 1983 57, 356-359 7.
- [14] Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, & Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with Polycystic ovary syndrome. *Human Reproduction* 2000 15, 1266-1274
- [15] Dunaif A, Graf M, Mandeli J, Laumas V, & Dobrjansky A. Characterization of group of hyperandrogenic women with acanthosis nigricans impaired glucose tolerance, and/or hyperinsulinemia. *Journal of Clinical Endocrinology and Metabolism* 1987 65, 499-507
- [16] Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapani Ed, & Bartzis MI. A survey of the Polycystic ovary syndrome in the greek island of Lesbos: hormonal and metabolic profile. *Journal of Clinical Endocrinology and Metabolism* 1999 84, 4006-4011

- [17] Wild RA, Painter PC, Counlson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with Polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism* 1985; 61,946-51 11.
- [18] Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the Polycystic ovary syndrome:relation to anthropometric, endocrine and metabolic variables. *Clinical Endocrinology* 1994; 41: 463-71
- [19] Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dylipidemia in PCOS, *Trends in Endocrinology and Metabolism* 2007 Sep;18(7):280-5
- [20] Coviello AD, Richard S, Legro, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. *Journal of Clinical Endocrinology and metabolism* 2006 Feb;91(2):492-7.
- [21] Orio F Jr, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A, Lombardi. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? *Reprod Biomed Online Journal*. 2004 Nov;9(5):505-10
- [22] Lewy UD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girl with polycystic ovarian syndrome. *Journal of Pediatric* 2001 138: 38-44
- [23] Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women ith polycystic ovary syndrome: influence of the diet. *Hum Reprod* 2003 18: 2289-93
- [24] Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. *Journal of Clinical Endocrinology and metabolism* 1999 84:1897-1899
- [25] Piccione E, Dei M Donna Domani, CIC Edizioni Internazionali
- [26] Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ; Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. *Journal of Clinical Endocrinology and metabolism* 2002 87:1017-1023
- [27] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and  $\beta$ cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985 28; 412-419
- [28] Ferriman D, Gallwey JD. Clinical Assesmentof body hair growth in women. *Journal of Clinical Endocrinology and metabolism* 1960 21:1440 – 1447
- [29] Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. *Journal of Clinical Endocrinology and metabolism* 2000 May;85(5)
- [30] Pasquali R. Obesity and androgens: facts and perspectives; *Fertil Steril* 2006 May;85(5):1319-40
- [31] Brown GA, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, King DS. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. *Journal of Clinical Endocrinology and metabolism* 2000 Nov;85(11):4074-80

- [32] Tan KC, Shiu SW, Kung AW. Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. *Clinical Endocrinology (Oxf)* 1999 51, 765-769

IntechOpen

IntechOpen



## **Dyslipidemia - From Prevention to Treatment**

Edited by Prof. Roya Kelishadi

ISBN 978-953-307-904-2

Hard cover, 468 pages

**Publisher** InTech

**Published online** 03, February, 2012

**Published in print edition** February, 2012

Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and environmental factors. It has many adverse health impacts, notably in the development of chronic non-communicable diseases. Significant ethnic differences exist due to the prevalence and types of lipid disorders. While elevated serum total- and LDL-cholesterol are the main concern in Western populations, in other countries hypertriglyceridemia and low HDL-cholesterol are more prevalent. The latter types of lipid disorders are considered as components of the metabolic syndrome. The escalating trend of obesity, as well as changes in lifestyle and environmental factors will make dyslipidemia a global medical and public health threat, not only for adults but for the pediatric age group as well. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and treatment.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Annamaria Fulghesu and Roberta Magnini (2012). Obesity Related Lipid Profile and Altered Insulin Incretion in Adolescent with Polycystic Ovary Syndrome, *Dyslipidemia - From Prevention to Treatment*, Prof. Roya Kelishadi (Ed.), ISBN: 978-953-307-904-2, InTech, Available from:

<http://www.intechopen.com/books/dyslipidemia-from-prevention-to-treatment/obesity-related-lipid-profile-and-altered-insulin-incretion-in-adolescent-with-pcos>

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821



© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen